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Pivotal to the regulation of key cellular processes such as the transcription,
replication and repair of DNA, DNA-binding proteins play vital roles in all
aspects of genetic activity. The determination of high-quality structures of DNA-
binding proteins, particularly those in complexes with DNA, provides crucial
insights into the understanding of these processes. The presence in such
complexes of phosphate-rich oligonucleotides offers the choice of a rapid
method for the routine solution of DNA-binding proteins through the use of
long-wavelength beamlines such as I23 at Diamond Light Source. This article
reports the use of native intrinsic phosphorus and sulfur single-wavelength
anomalous dispersion methods to solve the complex of the DNA-binding
domain (DBD) of interferon regulatory factor 4 (IRF4) bound to its interferon-
stimulated response element (ISRE). The structure unexpectedly shows three
molecules of the IRF4 DBD bound to one ISRE. The sole reliance on native
intrinsic anomalous scattering elements that belong to DNA–protein complexes
renders the method of general applicability to a large number of such protein
complexes that cannot be solved by molecular replacement or by other phasing
methods.
1. Introduction
DNA-binding proteins are essential components of all bio-
logical systems, where they perform crucial roles. Deregulation
or mutation of DNA-binding proteins, such as transcription
factors, is closely associated with the pathogenesis of several
human diseases, including cancer, making them attractive
therapeutic targets (Lee & Young, 2013; Hudson & Ortlund,
2014). Structure solution of protein–DNA complexes provides
the basis of our understanding of normal and pathogenic DNA
metabolism and underpins attempts to develop novel drugs
targeting disease-associated DNA-binding proteins (Bush-
weller, 2019). The last ten years have witnessed a step-change
increase in the number of experimentally determined protein–
nucleic acid complexes. More than two thirds of all structures
of complexes deposited in the Protein Data Bank (PDB) as of
April 2021 (6145 out of 9204) were solved in the last ten years.
However, the number of protein–nucleic acid complex struc-
tures solved remains only a small part of the deposited
structures as their experimental determination often remains
challenging. The lack of suitable homologous structures can be
an obstacle to solving the crystallographic phase problem.
Even when molecular replacement (MR) can be employed,
DNA-binding proteins can be flexible and/or disordered
ISSN 2053-230X
(Munshi et al., 2018; Dyson & Komives, 2012; Varadi et al.,
2015), whilst nucleic acids can depart from canonical struc-
tures (Tateishi-Karimata & Sugimoto, 2020). Occasionally,
multiple conformational folds are displayed, producing highly
dynamic structural ensembles (Fuxreiter et al., 2011). As a
result, MR alone can often deliver electron-density maps that
are of poor quality and are unsuitable for model building and
structure solution.
Experimental phasing sidesteps the lack of homologous
structures and helps in obtaining interpretable electron-
density maps; however, the artificial addition of anomalous
scatters by heavy-atom derivatization or selenomethionine
substitution can be a time-consuming and often arduous task.
On the other hand, native single-wavelength anomalous
dispersion (SAD) phasing using the weak anomalous scat-
tering signal of light atoms that are intrinsically present in
proteins and nucleic acids, such as phosphorus, sulfur,
chlorine, potassium and calcium, obviates the need for cova-
lent or noncovalent heavy-atom modifications. In comparison
with metals, however, the anomalous scattering signal from
these light atoms is relatively small, and native SAD phasing is
critically dependent on accurate recording (Rose & Wang,
2016). The challenges associated with native SAD phasing are
illustrated by the observation that whilst the first native SAD
structure was reported in 1981 (Hendrickson & Teeter, 1981),
it took almost 20 years for more structures to be solved
(Dauter et al., 1999; Liu et al., 2000) by using solvent-flattening
approaches (Wang, 1985). Over the past 20 years, advances in
hardware, software, data-collection methods and strategies
have allowed the collection of highly accurate data with an
increase in the anomalous signal-to-noise ratio, which in turn
has enabled the ‘routine’ use of native SAD phasing for de
novo structure solution (Rose et al., 2015). Furthermore, the
use of native SAD phasing, for example from S atoms, has
been successfully used in combination with MR (MRSAD) to
overcome model bias and assist with phasing, model building
and refinement (Schuermann & Tanner, 2003).
The use of the intrinsic anomalous signal of phosphorus to
phase oligonucleotide crystal diffraction data using SAD
(P-SAD) was first theoretically and practically demonstrated
in 2001 (Dauter & Adamiak, 2001). However, when not in
complex with proteins, phasing of nucleic acid structures using
P-SAD is very challenging and has in effect been limited to a
very small number of cases where crystals diffracted to high
resolution (Raiber et al., 2015; Luo et al., 2014). There are two
possible explanations for the lack of success of P-SAD on
nucleic acid structures: the high mobility and consequent high
B factors of P atoms in the nucleic acid backbone (Harp et al.,
2016) and the reduced number of reflections available for
phasing compared with the large number of P atoms (typically
small unit cells and often high-symmetry space groups). Lower
B factors and a higher ratio of reflections to sites in the
substructure have been shown to be crucial for SAD phasing
in general (Terwilliger et al., 2016). On the other hand, because
interactions with proteins usually stabilize nucleic acid back-
bones and the number of reflections is greater in larger unit
cells, P-SAD can be routinely used for phasing protein–nucleic
acid complexes as long as the anomalous signal can be
precisely retrieved. The level of difficulty of extracting the
intrinsic anomalous signal at in-house or synchrotron beam-
line wavelengths can be appreciated from a graph of f 0 and f 00
of phosphorus, as seen in Fig. 1. In practice, the signal-to-noise
ratios necessary to adequately and routinely retrieve the
anomalous signal of phosphorus are achievable only with very
high multiplicity data or at wavelengths that are only obtain-
able at state-of-the-art long-wavelength beamlines such as I23
at Diamond Light Source. This beamline operates under
vacuum with a large semi-cylindrical detector (PILATUS
12M, Dectris) to minimize absorption effects and allow
measurements of larger diffraction angles at longer wave-
lengths (Wagner et al., 2016).
Here, the structure of the DNA-binding domain (DBD) of
interferon regulatory factor 4 (IRF4) bound to its interferon-
stimulated response element (ISRE), solved by the use of
native intrinsic phosphorus and sulfur single-wavelength
anomalous dispersion methods at I23, is presented. The
structure shows the presence of three molecules of the IRF4
DBD bound to one molecule of DNA, which is unexpected in
the light of previous studies suggesting the homodimerization
of IRF4 on ISRE elements (Ochiai et al., 2013). This study
suggests that native intrinsic SAD methods can be used
successfully and routinely on long-wavelength beamlines such
as I23 to solve protein–nucleic acid structures de novo, elim-
inating the need for molecular replacement.
2. Materials and methods
2.1. Protein expression and purification
The IRF4 DBD (amino acids 20–139) was cloned into a
pCDFDuet-1 bacterial expression plasmid containing an
N-terminal 6His tag, transformed into the Esherichia coli
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Figure 1
Theoretical values of f 0 and f 0 0 for the elements sulfur (purple) and
phosphorus (green) over energies from 1.5 to 20 keV. The grey bar
indicates the wavelength/energy (2.7552 Å/4.5 keV) at which the IRF4
DBD–ISRE DNA data sets were collected. The plot was generated using
the http://www.bmsc.washington.edu/scatter website.
BL21 strain (Novagen) and grown at 310 K by shaking at
180 rev min1 in Luria–Bertani (LB) broth until the absor-
bance at 600 nm reached a value of 0.6. Overexpression of the
fusion protein was induced by the addition of 0.4 mM
isopropyl -d-1-thiogalactopyranoside (IPTG) and growth
was continued for 16 h at 291 K. The cells were harvested by
centrifugation, resuspended in lysis buffer [25 mM HEPES pH
7.4, 150 mM NaCl, 5 mM imidazole, 0.1 mM MgCl2, 0.01%
Triton X-100, 0.5 mM tris(2-carboxyethyl)phosphine (TCEP),
protease-inhibitor cocktail] and lysed by sonication on ice. The
lysate was clarified by centrifugation at 26 700g for 45 min at
277 K. The supernatant was applied onto a HisPur Cobalt
Resin column (Thermo Fisher) previously equilibrated with
wash buffer (25 mM HEPES pH 7.4, 150 mM NaCl, 5 mM
imidazole, 0.5 mM TCEP). Following a 10 min incubation at
227 K and the application of five column volumes of wash
buffer, the protein was eluted by the addition of elution buffer
(25 mM HEPES pH 7.4, 150 mM NaCl, 150 mM imidazole,
0.5 mM TCEP). The collected eluate was concentrated and
purified by size-exclusion chromatography using a HiLoad
16/600 Superdex 75 prep-grade column (GE Healthcare) in
gel-filtration buffer (20 mM Tris–HCl pH 8, 500 mM NaCl,
0.5 mM TCEP) at 277 K. Fractions were analysed on a 14%
SDS–PAGE gel by electrophoresis and those containing the
IRF4 DBD were pooled and concentrated to 10 mg ml1.
Oligonucleotides containing an interferon response element
(ISRE), 50-AATAAAAGAAACCGAAAGTAA-30 and 50-
TTTACTTTCGGTTTCTTTTAT-30 (Eurofins Genomic),
were annealed and incubated in a 1.2:1 DNA:protein molar
ratio for 1 h at 277 K prior to crystallization.
2.2. Crystallization
The IRF4 DBD–ISRE complex was used to screen 384
conditions using the sitting-drop vapour-diffusion method.
Initial hits appeared within a week and were optimized with an
additive screen (JBScreen Plus HTS). The best crystals grew in
0.1 M sodium acetate pH 5.2, 5% PEG 4000, 10 mM EDTA at
293 K. Crystals were harvested using sample holders designed
specifically for experiments on the in-vacuum I23 beamline
and were successfully cryoprotected in 25% glycerol by flash-
cooling in liquid nitrogen.
2.3. Data collection and processing
Diffraction data from two crystals of the IRF4 DBD–DNA
complex were collected on a PILATUS 12M detector
(Dectris) at 60 K on the long-wavelength beamline I23 at
Diamond Light Source, Didcot, UK (Wagner et al., 2016).
From each crystal, four data sets of 360 (rotation increment
0.1, exposure 0.1 s) were collected with different  and ’
angles at a wavelength of 2.7552 Å (energy 4.5 keV). The eight
data sets were each processed independently with XDS and
then merged together with XSCALE (Kabsch, 2010) in space
group C2221. Intensities were subsequently scaled to ampli-
tudes in AIMLESS (Evans & Murshudov, 2013).
2.4. Structure solution and refinement
Structure solution was performed using native SAD tech-
niques. The automatic experimental phasing pipeline Crank2
(Skubák & Pannu, 2013) using PRASA with 20 000 trials and a
resolution cutoff of 3.2 Å found a substructure of 39 atoms
with an occupancy of at least 25%. The pipeline provided an
interpretable electron-density map and a starting model in
which three IRF4 DBD molecules could be identified. The
electron-density map quality and the location of the phos-
phorus sites allowed the manual building of the double-
stranded DNA, since the pipelines is not yet able to build
nucleic acids, and improvement of the IRF4 DBD molecules in
Coot (Emsley et al., 2010). Refinement was carried out with
phenix.refine (Liebschner et al., 2019) with a strategy
consisting of positional, individual B factor, TLS and NCS
refinement. The final IRF4 DBD–DNA complex structure was
refined to 2.6 Å with an Rwork and Rfree of 21.2% and 24.1%,
respectively, and was validated with MolProbity (Chen et al.,
2010). The final refined structure is composed of three mole-
cules of IRF4 (residues 21–134, 22–130 and 19–130, respec-
tively) and the 21 base pairs of ISRE DNA. Data-collection
and refinement details are presented in Table 1.
3. Results
The human IRF4 DBD domain was expressed, purified and
co-crystallized with 21-mer DNA with an AT 50 overhang
containing an ISRE element. Diffraction data were initially
collected at a wavelength of 0.9795 Å on beamline I04 at
Diamond Light Source. A complete data set was collected to a
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Table 1
Data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
Wavelength (Å) 2.755
No. of crystals 2
Resolution range (Å) 64.02–2.60 (2.69–2.60)
Space group C2221
a, b, c (Å) 77.9, 112.4, 140.7
, ,  () 90, 90, 90
Total No. of reflections 1562438 (150892)
Unique reflections 19282 (1865)
Overall multiplicity 81.0 (66.1)
Completeness (%) 99.24 (98.10)





R.m.s.d., bond lengths (Å) 0.010













resolution limit of 2.75 Å from a crystal belonging to space
group C2221, with unit-cell parameters a = 78.2, b = 112.5,
c = 139.4 Å. The identification of the content of the crystal
asymmetric unit via analysis of the Matthews coefficient was
not unambiguous. The most likely oligomeric state, as
suggested by previous studies (Ochiai et al., 2013), is that of an
IRF4 homodimer bound to one ISRE element, suggesting a
molecular weight for the complex of about 44.8 kDa. The
volume of the crystal asymmetric unit is compatible with the
presence of either one (VM = 3.4 Å
3 Da1, solvent content
64%) or two (VM = 1.7 Å
3 Da1, solvent content 28%) copies
of such a complex. Initial attempts to solve the structure by
molecular replacement using the NMR structure of the IRF4
DBD (PDB entry 2dll; RIKEN Structural Genomics/Proteo-
mics Initiative, unpublished work) to search for either one or
two copies of the complex were unsuccessful. Automatic
molecular-replacement programs such as Phaser.MRage
(Bunkóczi et al., 2013), where the asymmetric unit content can
be left for the program to establish even when the number of
copies of a single component are unknown, were also unsuc-
cessful. Several reasons including conformational differences
between the model and the data or inherent inaccuracies in
the NMR model could account for the failure of this approach.
Taking advantage of the dedicated long-wavelength beam-
line I23 at Diamond Light Source, data were collected at a
wavelength of 2.7552 Å with the aim of solving the structure of
the complex de novo using native intrinsic phosphorus and
sulfur SAD methods. The wavelength choice, guided by the
experience of previous successful experiments on beamline
I23, is a compromise between anomalous signal strength and
absorption effects that decrease the data quality. Absorption
increases with the cube of the wavelength and although in a
high-vacuum environment there is no air absorption, absorp-
tion by the crystal, the sample holder and the surrounding
mother liquor together can have a severe impact on the
recorded intensities at long wavelengths. The impact on
intensities is further exacerbated if the X-ray path length
varies significantly depending on the crystal orientation. The
limitations of native SAD phasing experiments that use
wavelengths longer than 3 Å have previously been described
(Basu et al., 2019). At a wavelength of 2.7552 Å, S and P atoms
contribute with anomalous differences f 00 of 1.6 e and 1.3 e,
respectively (Fig. 1). The final high-multiplicity (80) data set
to a resolution of 2.6 Å (space group C2221, unit-cell para-
meters a = 77.9, b = 112.4, c = 140.7 Å) was obtained by
merging eight data sets collected from two crystals: four data
sets from each crystal.
PRASA, as part of the automatic structure-determination
pipeline Crank2, was able to locate 39 atoms of the
substructure within which the DNA double helix could be
readily recognized (Fig. 2a). The substructure was used to
produce an interpretable electron-density map in which,
surprisingly, three IRF4 DBD molecules were identified
(Fig. 2b). The quality of the electron-density map and the
phosphorus sites were instrumental in the manual building of
the DNA oligonucleotide since the Crank2 pipeline does not
support the automatic building of nucleic acids. Iterative
cycles of manual model building with Coot and refinement
with phenix.refine allowed full structure determination. The
final model contained three molecules of the IRF4 DBD
bound to one ISRE element, which fits well in the crystallo-
graphic asymmetric unit (VM = 2.5 Å
3 Da1, solvent content
51%) based on an estimated molecular mass of 61 kDa.
When calculating phased anomalous difference maps with
ANODE (Thorn & Sheldrick, 2011), the three IRF4 DBD
sulfur sites gave anomalous peaks that were stronger on
average than the DNA phosphorus sites (11 versus 9);
however, one of the sulfur sites had a much lower peak height
when compared with the other two sites (4 compared with
18 and 13) (Fig. 2a). The corresponding IRF4 DBD
molecule displays poorly defined electron density and higher
B factors when compared with the other two IRF4 DBD
molecules in the asymmetric unit (167 Å2 when compared with
87 and 112 Å2), as shown in Fig. 3.
Previous studies using electrophoretic mobility shift assays
suggested that IRF4 binds the ISRE element as a homodimer
with low affinity (Ochiai et al., 2013). The finding of three
molecules bound to ISRE is unexpected, and a full structural
and biophysical analysis of binding affinities is currently under
way.
4. Discussion
Although native SAD remains a challenging method for the
solution of nucleic acid crystal structures (Harp et al., 2016),
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Figure 2
Difference Fourier anomalous map and experimental electron-density map
for the IRF4 DBD. (a) Difference Fourier anomalous map contoured at
5 generated by Crank2 from the partially built model (no nucleic acids
built). The grey electron density corresponds to P atoms from the DNA
molecule, and the blue electron density, in the major DNA groove, to the
S atoms from the IRF4 DBD. The weaker electron density at the very top
of the picture corresponds to the S atom from the third IRF4 DBD
molecule. (b) Experimental electron-density map generated by Crank2.
The final model of the IRF4 DBD is fitted in the map to assess the map
quality. This figure was prepared with PyMOL (version 2.0; Schrödinger).
this is not the case for protein–nucleic acid complexes. Native
intrinsic phosphorus and sulfur SAD was chosen as a fast and
elegant method for the determination of the IRF4 DBD–DNA
complex structure. This technique does not rely on seleno-
methionine substitution or heavy-atom derivatization, but
instead measures the anomalous signal from light atoms that
are naturally present in proteins and nucleic acids. As the
error associated with the measurement decreases with the
square of the number of observations, a high-multiplicity data
set was obtained by collecting and merging eight diffraction
data sets collected from two different crystals. The individual
data sets were collected at different  and ’ angles to minimize
systematic error due to the experimental setup. As the I23
beam is unfocused, the beam flux is reduced, allowing multiple
sweeps of 360 of data to be collected at low dose using the
settings described in Section 2. Data collection is brought to an
end when signs of radiation damage are detected, either via a
decrease in the anomalous signal resolution or a decrease in
the number of reflections recorded during data collection, by
using Diffraction Image Screening Tool and Library (DISTL)
software plots (Zhang et al., 2006). The merging of the data
sets increases the Bijvoet multiplicity at the same time as
limiting the radiation damage. The higher redundancy
increases the accuracy of the data and the strength of the
anomalous signal to noise of the data set (Liu et al., 2012).
Of the 45 anomalous scatterers in the asymmetric unit (42 P
atoms in the double-stranded DNA and one S atom per IRF4
DBD molecule), 39 could be initially identified by PRASA,
providing sufficient anomalous signal to phase the whole
complex. Of the three S atoms, however, one produced a very
weak anomalous signal when compared with the other two.
This sulfur belongs to an IRF4 DBD molecule with poorly
defined electron density and higher B factors. With only two
strong anomalous sulfur sites, it could be argued that the
structure of this specific complex could have been solved using
the phosphorus substructure alone. A further advantage of
solving the phosphorus substructure was that the DNA double
helix was readily recognisable and the electron-density map
for the nucleic acid portion of the structure was strong. The
phosphorus sites were used as well defined guides for fitting
and building the DNA double-helix model, which is important
when, as in this case, the DNA departs from the canonical B
form (Fig. 3).
Native intrinsic SAD phasing is particular helpful when
homologous models for molecular replacement are not
available, when molecular replacement is not successful and/
or when the initial electron-density maps are not suitable for
model building. At the time of this study, only an NMR model
of the IRF4 DBD domain was available as a molecular-
replacement model and it did not lead to a clear phasing
solution. The molecular-replacement procedure was
confounded by the unexpected oligomerization state of the
complex: a heterotetramer with three IRF4 DBD molecules
bound to one ISRE element. Furthermore, one of the three
IRF4 DBD molecules in the asymmetric units displayed poor
electron density and high B factors (Fig. 3), which might also
explain the difficulty in solving the structure of the complex by
molecular replacement.
Despite the challenges associated with the technique, native
SAD phasing is on the brink of becoming the routine method
of choice for de novo structure determination (Rose et al.,
2015). The availability of dedicated long-wavelength beam-
lines to increase the anomalous scattering signal of intrinsic
light atoms has been instrumental in the increasing popularity
of the method. Protein–DNA complexes are especially good
candidates for native SAD phasing at long wavelengths since
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Figure 3
Crystal structure of the IRF4 DBD on ISRE DNA. The IRF4 DBD is in a B-factor putty cartoon representation, where the cartoon thickness and colour
reflect the relative C B factors within the molecule. The ISRE DNA is coloured magenta. The A-weighted 2Fo  Fc refined map is shown (grey mesh)
at a contour level of 1.5. The map, focusing on one of the recognition helices, was carved around the atomic model of the IRF4 DBD with a border of
2 Å to improve clarity. This figure was prepared with PyMOL (version 2.0; Schrödinger).
the technique is particularly suited for sulfur and phosphorus
substructure detection. To conclude, this work suggests that by
using long-wavelengths beamlines, such as I23 at Diamond
Light Source, this method could be generally applicable to a
large number of nucleic acid–protein complexes.
Acknowledgements
We would like to thank Diamond Light Source for beamtime
allocation and access. Author contributions were as follows:
AA, KEO and RD performed experiments; KEO solved the
crystal structures; AA, KEO, AW and EJM wrote the manu-
script; EJM supervised the overall study.
Funding information
This research was supported by a Wellcome Trust Institutional
Strategic Support Fund award (204833/Z/16/Z). For the
purpose of open access, the author has applied a CC BY public
copyright licence to any author accepted manuscript version
arising from this submission.
References
Basu, S., Olieric, V., Leonarski, F., Matsugaki, N., Kawano, Y.,
Takashi, T., Huang, C.-Y., Yamada, Y., Vera, L., Olieric, N.,
Basquin, J., Wojdyla, J. A., Bunk, O., Diederichs, K., Yamamoto, M.
& Wang, M. (2019). IUCrJ, 6, 373–386.
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